ZIOPHARM Oncology Inc (ZIOP) Lowered to Sell at BidaskClub
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Monday.
ZIOP has been the topic of several other reports. HC Wainwright started coverage on shares of ZIOPHARM Oncology in a research report on Thursday, June 1st. They set a “buy” rating and a $9.50 price objective on the stock. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, April 26th. Finally, ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $13.17.
ZIOPHARM Oncology (ZIOP) opened at 5.51 on Monday. The stock has a 50 day moving average of $5.89 and a 200 day moving average of $6.34. ZIOPHARM Oncology has a 12-month low of $4.84 and a 12-month high of $7.88. The company’s market cap is $774.88 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. The firm’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.01) earnings per share. Equities analysts expect that ZIOPHARM Oncology will post ($0.56) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “ZIOPHARM Oncology Inc (ZIOP) Lowered to Sell at BidaskClub” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/16/ziopharm-oncology-inc-ziop-lowered-to-sell-at-bidaskclub.html.
A number of hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth about $5,556,000. Teachers Advisors LLC increased its stake in shares of ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock worth $1,062,000 after buying an additional 3,699 shares in the last quarter. Highbridge Capital Management LLC bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth about $164,000. Creative Planning increased its stake in shares of ZIOPHARM Oncology by 289.3% in the first quarter. Creative Planning now owns 57,863 shares of the biotechnology company’s stock worth $367,000 after buying an additional 43,000 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in shares of ZIOPHARM Oncology by 6.2% in the first quarter. Janney Montgomery Scott LLC now owns 266,366 shares of the biotechnology company’s stock worth $1,689,000 after buying an additional 15,610 shares in the last quarter. Institutional investors own 38.17% of the company’s stock.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Stock Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related stocks with our FREE daily email newsletter.